GrowBlox Sciences, Inc is a Las Vegas, Nevada-based solutions provider to medical cannabis cultivators and processors. Currently in development state, this company develops proprietary technologies that it plans to implement in the area with the help of its state-level partners.
The company’s technologies are designed to improve various aspects of the cannabis cultivation and production. First, a foremost product of GrowBlox Sciences is an indoor plant-growing space called the GrowBlox Cannabis Grow Chamber, equipped with climate and environmental controls. Similarly, the company offers the InCUBEator Cannabis Propagation Chamber, also a controlled space that ensures consistency in cannabis cultivation through tissue culture method.
GrowBlox also has a technology for extracting medicinal cannabis compounds. This is called the ConversionLAB, and it is touted to ensure clean extracts because it uses CO2. Finally, for drying and curing marijuana, GrowBlox has the CureBLOX Cannabis Drying System, an algorithm-based technology that controls temperature and humidity and eliminates pathogens.
In addition to providing technologies, GrowBlox Sciences presents itself as one of the leaders in processing licenses. Offering state and local license processing, the company’s specialists cover application requests such as branding, compliance, packaging, sales plans, and security.
GrowBlox Sciences, Inc was founded in 2001 under the name Flagstick Ventures, Inc. In 2004, it changed its name and business to the Diabetic Treatment Centers of America, Inc. It changed again in 2008 to Signature Exploration and Production Corp. Then, in 2014, it finally changed to its current name and business.
GrowBlox Sciences, Inc. is now traded as GBLX in the OTC markets. It has a market cap of USD 22.41 M.
Leaders at GrowBlox include Chairman and CEO Craig M. Ellins, CFO and Chief Accounting Officer Steven W. Weldon, and Chief Science Officer Dr. Andrea Small Howard.
GrowBlox Sciences, Inc.
7251 West Lake Mead Blvd
Las Vegas, NV 89128
Phone: (844) 843-2569
Yahoo! Finance: GBLX News
Latest Financial News for GBLX
LAS VEGAS , Oct. 9, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. Dr. Andrea Small-Howard , GB Sciences' Chief Science Officer and Director, explains why GB Sciences is well-positioned to provide research-supported product formulations for both market segments.
LAS VEGAS, Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations. Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out. The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations. The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location.
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
LAS VEGAS , Aug. 28, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.
Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.